Skip to main content
SpringerLink
Log in

Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Hormone replacement therapy (HRT) prevents postmenopausal bone loss, and is therefore increasingly prescribed to prevent the development of postmenopausal osteoporosis. Because of individual differences in the response to HRT as well as problems with compliance, it has been debated how the skeletal response to HRT should be monitored. When estrogen production decreases at the menopause, a number of biochemical markers of bone turnover increase considerably in the order of 50%–100% from baseline. When HRT is instituted, the markers decrease again within the following 3–6 months. In the present prospective study we investigated whether the determination of biochemical markers of bone turnover may be useful for monitoring the skeletal effect of HRT. Seventy-six early postmenopausal women received HRT and 43 received placebo. The treatment period was 24 months and the women were followed with repeated bone mass measurements (every 3 months) which allowed calculation of the bone loss. Serum and urine samples were collected at 3, 6, 12 and 24 months. The placebo group lost a significant amount of bone mineral density in both the forearm and the spine (p<0.001), whereas the HRT group did not. There was, however, a relatively large overlap of values between the HRT and placebo groups, especially in the spine. After 3 months' treatment the correlation between the changes in the markers and the bone loss wasr=0.59, and this value increased tor=0.66 at 6 months andr=0.76 andr=0.77 at 12 and 24 months, respectively. The present study thus indicates that biochemical markers of bone turnover may be of value for monitoring the bone response to HRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Christensen MS, Hagen C, Christiansen C, Transbøl I. Dose-response evaluation of cyclic estrogen/gestagen in postmeno-pausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873–9.

    PubMed  Google Scholar 

  2. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–63.

    PubMed  Google Scholar 

  3. Heaney RP. En recherche de la difference (p<0.05). Bone Miner 1986;1:99–114.

    PubMed  Google Scholar 

  4. Johnston CC Jr, Hui SL, Witt RM, Appledorn R, Baker RS, Longcope C. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 1985;61:905–11.

    PubMed  Google Scholar 

  5. Riis BJ, Thomsen K, Strøm V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–5.

    PubMed  Google Scholar 

  6. Riis BJ, Jensen J, Christiansen C. Cyproterone acetate, and alternative gestagen in postmenopausal oestrogen/gestagen therapy. Clin Endocrinol 1987;26:327–34.

    Google Scholar 

  7. Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects of bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79:202–10.

    PubMed  Google Scholar 

  8. Marslew U, Riis BJ, Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1991;21:601–7.

    PubMed  Google Scholar 

  9. Hansen MA, Riis BJ, Overgaard K, Hassager C, Christiansen C. Bone mass measured by photon absorptiometry: comparison of forearm, heel and spine. Scand J Clin Lab Invest 1990;50:517–23.

    PubMed  Google Scholar 

  10. Hassager C, Borg J, Christiansen C. Measurement of the subcutaneous fat in the distal forearm by single photon absorptiometry. Metabolism 1989;38:159–65.

    PubMed  Google Scholar 

  11. Hansen MA, Hassager C, Overgaard K, Marslew U, Riis BJ, Christiansen C. Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density on the lumbar spine. J Nucl Med 1990;31:1156–62.

    PubMed  Google Scholar 

  12. Johansen JS. Mølholm Hansen JE, Christiansen C. A radioimmunoassay for bone Gla protein (BGP) in human plasma. Acta Endocrinol 1987;114:410–6.

    PubMed  Google Scholar 

  13. Pødenphant J, Larsen N-E, Christiansen C. An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 1984;142:145–8.

    PubMed  Google Scholar 

  14. Persson I, Adami H-O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147–51.

    PubMed  Google Scholar 

  15. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293–7.

    PubMed  Google Scholar 

  16. Hassager C, Jensen SB, Christiansen C. Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss. Do they exist? Osteoporosis Int 1994;4:36–41.

    Google Scholar 

  17. Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:105–8.

    Google Scholar 

  18. Christiansen C, Riis BJ, Rødbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis Int 1990;1:35–40.

    Google Scholar 

  19. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961–4.

    PubMed  Google Scholar 

  20. Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–5.

    PubMed  Google Scholar 

  21. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477–9.

    PubMed  Google Scholar 

  22. Meunier PJ, Delmas PD, Chaumet-Riffaud PD. Intranasal salmon calcitonin for prevention of postmenopausal bone loss: a placebo-controlled study in 109 women. In: Christiansen C, Overgaard K, editors. Proceedings of the third international symposium on osteoporosis. Copenhagen, Denmark: Osteopress ApS 1990;1861–7.

    Google Scholar 

  23. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.

    PubMed  Google Scholar 

  24. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.

    PubMed  Google Scholar 

  25. Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87–96.

    PubMed  Google Scholar 

  26. Delmas PD, Schlemmer A, Gineyts E, Riis BJ, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone miner Res 1991;6:639–44.

    PubMed  Google Scholar 

  27. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–73.

    PubMed  Google Scholar 

  28. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635–41.

    PubMed  Google Scholar 

  29. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Clinical and Basic Research Ballerup Byvej 222, DK-2750, Ballerup, Denmark

    B. J. Riis, K. Overgaard & C. Christiansen

Authors
  1. B. J. Riis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Overgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riis, B.J., Overgaard, K. & Christiansen, C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporosis Int 5, 276–280 (1995). https://doi.org/10.1007/BF01774018

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01774018

Keywords

Search

Navigation